Zhejiang Cancer Hospital
🇨🇳China
Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction
Phase 4
Completed
- Conditions
- Postoperative Cognitive DysfunctionPostoperative Delirium
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT02923128
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)
Phase 2
- Conditions
- Small Cell Lung Cancer
- Interventions
- Radiation: hippocampus avoidance
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 154
- Registration Number
- NCT02906384
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT02878889
- Locations
- 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer
Phase 3
Completed
- Conditions
- Esophageal CancerChemoradiation
- Interventions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 298
- Registration Number
- NCT02813967
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Acquired Resistant Mechanism of the First-generation EGFR TKIs
- Conditions
- Non-small Cell Lung CancerAquired ResistanceEGFR TKIs
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02804217
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
Phase 3
- Conditions
- Neoadjuvant Therapy
- Interventions
- Drug: AC*4-T*4
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02769104
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Phase 2
- Conditions
- Pulmonary MetastasisHepatocellular Carcinoma
- Interventions
- Procedure: TACE
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02702323
Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2
- Conditions
- Glioblastoma Multiforme
- Interventions
- Radiation: Hypofractionated IMRTBiological: Granulocyte-macrophage Colony-stimulating Factor
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT02663440
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer
Phase 2
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Physician's choice chemotherapy
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02649101
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT02597868
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath